119 related articles for article (PubMed ID: 17353915)
1. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer.
Bucerius J; Ahmadzadehfar H; Hortling N; Joe AY; Palmedo H; Biersack HJ
Prostate Cancer Prostatic Dis; 2007; 10(3):307-10. PubMed ID: 17353915
[TBL] [Abstract][Full Text] [Related]
2. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract][Full Text] [Related]
3. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
Reesink DJ; Fransen van de Putte EE; Vegt E; De Jong J; van Werkhoven E; Mertens LS; Bex A; van der Poel HG; van Rhijn BW; Horenblas S; Meijer RP
J Urol; 2016 Apr; 195(4 Pt 1):907-12. PubMed ID: 26598424
[TBL] [Abstract][Full Text] [Related]
4. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
5. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level.
Minamimoto R; Uemura H; Sano F; Terao H; Nagashima Y; Yamanaka S; Shizukuishi K; Tateishi U; Kubota Y; Inoue T
Ann Nucl Med; 2011 Jan; 25(1):21-7. PubMed ID: 20931305
[TBL] [Abstract][Full Text] [Related]
6. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images?
Hwang I; Chong A; Jung SI; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K; Ryu SB
Ann Nucl Med; 2013 Feb; 27(2):140-5. PubMed ID: 23076866
[TBL] [Abstract][Full Text] [Related]
7. Significance of incidental focal uptake in prostate on 18-fluoro-2-deoxyglucose positron emission tomography CT images.
Han EJ; H O J; Choi WH; Yoo IR; Chung SK
Br J Radiol; 2010 Nov; 83(995):915-20. PubMed ID: 20965901
[TBL] [Abstract][Full Text] [Related]
8. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice.
Salminen E; Hogg A; Binns D; Frydenberg M; Hicks R
Acta Oncol; 2002; 41(5):425-9. PubMed ID: 12442917
[TBL] [Abstract][Full Text] [Related]
9. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
10. [Reply to editorial comment on article "Usefulness of PET scans in diagnosing recurrent prostate cancer. Prostate with PSA level <5ng/ml"].
Rioja Zuazu J; Zudaire Bergera JJ; Richter JA; Berián Polo JM
Actas Urol Esp; 2010 Jan; 34(1):12-4. PubMed ID: 20223128
[No Abstract] [Full Text] [Related]
11. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
12. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
Sung J; Espiritu JI; Segall GM; Terris MK
BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
[TBL] [Abstract][Full Text] [Related]
13. Incidental PET/CT findings in the cancer patient: how should they be managed?
Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical significance of incidental (18)F-fluoro-2-deoxyglucose uptake in prostate.
Kwon T; Jeong IG; You D; Hong JH; Ahn H; Kim CS
Korean J Urol; 2015 Apr; 56(4):288-94. PubMed ID: 25874042
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?
Greco C; Cascini GL; Tamburrini O
Prostate Cancer Prostatic Dis; 2008; 11(2):121-8. PubMed ID: 18180806
[TBL] [Abstract][Full Text] [Related]
16. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
17. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
[TBL] [Abstract][Full Text] [Related]
18. Interesting image. Incidental diagnosis of prostate cancer by F-18 FDG PET/CT.
Monet A; Merino B; Lupo R
Clin Nucl Med; 2010 Jan; 35(1):34-5. PubMed ID: 20026972
[No Abstract] [Full Text] [Related]
19. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
20. Use of 18F-choline positron emission tomography/CT in high-risk prostate cancer: a case of solitary adrenal metastasis.
Matrone F; Sivolella S; Bellavita R; Casciola L; Cristallini EG; Aristei C
Tumori; 2015 Mar; 101(1):e21-3. PubMed ID: 25702663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]